Expanded clinical phenotype and untargeted metabolomics analysis in RARS2-related mitochondrial disorder: a case report

Ameya S. Walimbe,Keren Machol,Stephen F. Kralik,Elizabeth A. Mizerik,Yoel Gofin,Mir Reza Bekheirnia,Charul Gijavanekar,Sarah H. Elsea,Lisa T. Emrick,Fernando Scaglia
DOI: https://doi.org/10.1186/s12883-024-03571-w
2024-03-05
BMC Neurology
Abstract:RARS2 -related mitochondrial disorder is an autosomal recessive mitochondrial encephalopathy caused by biallelic pathogenic variants in the gene encoding the mitochondrial arginyl-transfer RNA synthetase 2 ( RARS2 , MIM *611524, NM_020320.5). RARS2 catalyzes the transfer of L-arginine to its cognate tRNA during the translation of mitochondrially-encoded proteins. The classical presentation of RARS2 -related mitochondrial disorder includes pontocerebellar hypoplasia (PCH), progressive microcephaly, profound developmental delay, feeding difficulties, and hypotonia. Most patients also develop severe epilepsy by three months of age, which consists of focal or generalized seizures that frequently become pharmacoresistant and lead to developmental and epileptic encephalopathy (DEE).
clinical neurology
What problem does this paper attempt to address?